Parents of children with treatment-resistant epilepsy are searching for something to help, and some are turning to cannabis to try to reduce seizure frequency.
With clinical trials of cannabidiol-based drugs under way, evidence for this treatment option may soon be forthcoming. However, concerns remain about side effects, such as sedation, interactions with other drugs, and potential disturbances of brain development.
Read this story at Pharmaceutical Journal.
When a patient seeks help for depression, the doctor plays a primitive guessing game to find an effective antidepressant. It takes weeks to months to determine whether a drug really works, leaving many disabled and some to lose hope.
Now, researchers are seeking a way to match people with depression to an effective drug at the outset of their treatment by searching for tell-tale features that could predict how they will respond. This personalised approach draws on a range of measures, including genetic variation, inflammation-related molecules, and brain function.
Read this story at Pharmaceutical Journal.
Genetic discoveries have invigorated autism research and raised the possibility of finding drug targets based on autism’s underlying pathophysiology, rather than merely treating symptoms.
Read this story at Pharmaceutical Journal.
Some researchers argue that slowing the rate of biological aging could be the best way to delay development of chronic diseases, such as cardiovascular disease, cancer and arthritis.
Read this story at Pharmaceutical Journal.
As more people are diagnosed with celiac disease, the first drug treatments are entering clinical trials. These drugs are geared toward supplementing, or even replacing, the gluten-free diet, which is currently the only treatment available. But success is proving difficult to measure.
Read this story at Pharmaceutical Journal.
With rates of heron addiction stubbornly high, there is still debate about how best to treat those hooked on the drug.
Read this story at Pharmaceutical Journal.
